IGBA Builds On Partnership With WHO
Collaborating On Widening Access And Promoting Uptake
In the first in a series of exclusive interviews, IGBA chair Hanan Sboul talks about the international off-patent industry association’s collaboration with the WHO and how it is expected to develop in future.
You may also be interested in...
The International Generic and Biosimilar Medicines Association has named the IPA’s Sudarshan Jain as its new chair. While Celltrion’s chairman has stepped down, Coherus has added two members to its board of directors and Synthon has appointed a new CEO.
The World Health Organization has recently added further biosimilar versions of trastuzumab to its list of prequalified products, along with Roche’s original trastuzumab and rituximab brands, Herceptin and MabThera/Rituxan.
New UK licensing procedures for biosimilars are about to be set out by the MHRA that will reduce the clinical trial data burden for applicants.